A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Ofatumumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 05 Dec 2019 This trial has been completed in Lithuania, according to European Clinical Trials Database record.
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2019 Planned End Date changed from 26 Aug 2019 to 29 May 2020.